Loading clinical trials...
Loading clinical trials...
The purpose of this research is to evaluate and create a new clinical prediction model for CCHD screening that combines non-invasive measurements of oxygenation and perfusion.
This study will create and test an enhanced critical congenital heart defect (CCHD) screen that combines non-invasive measurements of oxygenation and perfusion in two ways. The first will use current equipment without automated interpretation and the second will require additional software/device but will automate the interpretation. To work towards development of those two algorithms in this stage of the study, the study team will download oxygen saturation (SpO2) and perfusion index (PIx) measurements from newborns with and without congenital heart disease (CHD) and apply statistical tests to the data afterwards to identify parameters to include in the newly developed screening algorithms. The overall objective is to create an automated screening algorithm to improve acyanotic CCHD detection, preventing morbidity and mortality associated with diagnoses missed by SpO2 screening. The central hypothesis is that the addition of non-invasive perfusion measurements to SpO2 will be superior to SpO2-alone screening for detection of acyanotic CCHD. The data collected during this study will be used to develop the two algorithms and the algorithms will be compared to the standard of care using statistical tests on the data after the fact (k-fold validation). The newly developed algorithms will not be tested in-situ on patients during this study.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Sutter Institute for Medical Research
Sacramento, California, United States
University of California-Davis
Sacramento, California, United States
UCSF Benioff Children's Hospital
San Francisco, California, United States
Northwell Health
New Hyde Park, New York, United States
University of Utah/Primary Children's Hospital
Salt Lake City, Utah, United States
Start Date
October 23, 2019
Primary Completion Date
December 12, 2021
Completion Date
December 12, 2021
Last Updated
February 3, 2022
543
ACTUAL participants
SpO2 and PIx Measurement
DIAGNOSTIC_TEST
Lead Sponsor
University of California, Davis
Collaborators
NCT05647213
NCT07042334
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions